NASDAQ · Medical - Devices
Treace Medical Concepts, Inc. (TMCI) Stock
$3.95
+1.94%
NASDAQ: TMCI
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Truist Securities Adjusts Price Target on Treace Medical Concepts to $4 From $2, Maintains Hold Rating
MT Newswires · Jul 16, 2026
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
GlobeNewswire · Jun 18, 2026
Sidoti Events, LLC's June Small-Cap Virtual Conference
ACCESS Newswire · Jun 16, 2026
Treace to Present at the Sidoti Small Cap Conference
GlobeNewswire · Jun 11, 2026
June 2026's Top Penny Stocks To Watch
Simply Wall St. · Jun 11, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held25.35%
Institutions Held56.95%
Institutions Float Held76.28%
Peer Comparison
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc. is led by CEO John T. Treace, employs 477 people, headquartered in US, publicly traded since 2021.
Treace Medical Concepts, Inc. (TMCI) stock trades at $3.95 with a market capitalization of $256.25M. The stock is valued at a price-to-earnings (P/E) ratio of -4.72, price-to-book of 4.22, price-to-sales of 1.39. Over the past 52 weeks the stock has ranged between $1.17 and $7.08, and currently trades 44.2% below its 52-week high.
On profitability, Treace Medical Concepts, Inc. generates a return on equity (ROE) of -74.06%, return on capital employed of -38.49%, an operating margin of -25.35%, a net profit margin of -28.99%.